Associations of Tumor Suppressor SPARCL1 with Cancer Progression and Prognosis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Sep 21

PMID 28927026

Citations 11

Authors

Ting Li

Xia Liu

Antai Yang

Wenjie Fu

Fuqiang Yin

Xiaoyun Zeng

Affiliations

Soon will be listed here.

Abstract

SPARC-like protein 1 (SPARCL1), a member of the family of secreted proteins which is acidic and rich in cysteine, is a potential tumor suppressor gene in most types of tumor. A systemic review and bioinformatics analysis was carried out to determine the associations between SPARCL1 and tumor progression and clinical factors. Downregulation of SPARCL1, thought to be regulated by epigenetic modifications including DNA methylation, serves important functions in tumor progression and development, with its regulatory functions on cell viability, migration, invasion, cell adhesion and drug resistance. Downregulation of SPARCL1 was markedly associated with a poor overall survival rate of patients with one of ≥7 solid tumors and predicted increased mortality in patients with one of ≥4 distinct tumor types. The present review indicated that SPARCL1 may be a therapeutic target for cancer treatment and a biomarker to determine prognosis.

Citing Articles

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.

The oncogenic functions of SPARCL1 in bladder cancer.

Li C, Yuan H, Chen J, Shang K, He H J Cell Mol Med. 2024; 28(22):e70196.

PMID: 39548034 PMC: 11567778. DOI: 10.1111/jcmm.70196.

3D geometry orchestrates the transcriptional landscape of metastatic neuroblastoma cells in a multicellular bone model.

Nasehi R, Abdallah A, Pantile M, Zanon C, Vogt M, Rutten S Mater Today Bio. 2023; 19:100596.

PMID: 36910273 PMC: 9999213. DOI: 10.1016/j.mtbio.2023.100596.

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.

He K, Li C, Yuan H, Jiang K, Deng G Pathol Oncol Res. 2022; 28:1610687.

PMID: 36483097 PMC: 9722748. DOI: 10.3389/pore.2022.1610687.

Glioblastoma microenvironment contains multiple hormonal and non-hormonal growth-stimulating factors.

Dahlberg D, Rummel J, Distante S, Antonio de Souza G, Stensland M, Mariussen E Fluids Barriers CNS. 2022; 19(1):45.

PMID: 35659255 PMC: 9166426. DOI: 10.1186/s12987-022-00333-z.

References

Esposito I, Kayed H, Keleg S, Giese T, Sage E, Schirmacher P . Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007; 9(1):8-17. PMC: 1803032. DOI: 10.1593/neo.06646. View

Isler S, Ludwig C, Chiquet-Ehrismann R, Schenk S . Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol. 2004; 25(4):1073-9. View

Jakharia A, Borkakoty B, Singh S . Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma. J Gastrointest Oncol. 2016; 7(2):278-83. PMC: 4783736. DOI: 10.3978/j.issn.2078-6891.2015.064. View

Yin F, Liu X, Li D, Wang Q, Zhang W, Li L . Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. Int J Oncol. 2013; 42(4):1305-16. DOI: 10.3892/ijo.2013.1819. View

Schraml P, Shipman R, Stulz P, Ludwig C . cDNA subtraction library construction using a magnet-assisted subtraction technique (MAST). Trends Genet. 1993; 9(3):70-1. DOI: 10.1016/0168-9525(93)90216-5. View

Yu Y, Chen Y, Ma J, Yu X, Yu G, Li Z . SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma. Tumour Biol. 2015; 37(3):4159-67. DOI: 10.1007/s13277-015-4206-4. View

Hurley P, Marchionni L, Simons B, Ross A, Peskoe S, Miller R . Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012; 109(37):14977-82. PMC: 3443123. DOI: 10.1073/pnas.1203525109. View

Sato T, Arai E, Kohno T, Takahashi Y, Miyata S, Tsuta K . Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer. 2014; 135(2):319-34. PMC: 4255314. DOI: 10.1002/ijc.28684. View

Li P, Qian J, Yu G, Chen Y, Liu K, Li J . Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol. 2011; 105(1):31-7. DOI: 10.1002/jso.22025. View

10.

Claeskens A, Ongenae N, Neefs J, Cheyns P, Kaijen P, Cools M . Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000; 82(6):1123-30. PMC: 2363342. DOI: 10.1054/bjoc.1999.1051. View

11.

Yu S, Yu J, Ge W, Hu H, Yuan Y, Zheng S . SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol. 2011; 17(15):2028-36. PMC: 3082758. DOI: 10.3748/wjg.v17.i15.2028. View

12.

Hedditch E, Gao B, Russell A, Lu Y, Emmanuel C, Beesley J . ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst. 2014; 106(7). PMC: 4110473. DOI: 10.1093/jnci/dju149. View

13.

Tai I, Dai M, Owen D, Chen L . Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 2005; 115(6):1492-502. PMC: 1090471. DOI: 10.1172/JCI23002. View

14.

Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage E . Gene expression profiling of human ovarian tumours. Br J Cancer. 2006; 95(8):1092-100. PMC: 2360705. DOI: 10.1038/sj.bjc.6603346. View

15.

Girard J, Springer T . Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995; 2(1):113-23. DOI: 10.1016/1074-7613(95)90083-7. View

16.

Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D . ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6(1):1-6. PMC: 1635162. DOI: 10.1016/s1476-5586(04)80047-2. View

17.

Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P . Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 2012; 18(19):5438-48. DOI: 10.1158/1078-0432.CCR-12-0124. View

18.

Mintz M, Sowers R, Brown K, Hilmer S, Mazza B, Huvos A . An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005; 65(5):1748-54. DOI: 10.1158/0008-5472.CAN-04-2463. View

19.

Lau C, Poon R, Cheung S, Yu W, Fan S . SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol. 2006; 210(4):459-68. DOI: 10.1002/path.2068. View

20.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann B, Strand D . SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol. 2013; 7(6):1019-30. PMC: 3838491. DOI: 10.1016/j.molonc.2013.07.008. View